

REMARKS

In the “Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures” (Notice) mailed September 9, 2005, Applicants are required to provide:

- (i) a statement that the content of the sequence listing information recorded in computer readable form is identical to the written Sequence listing; and
- (ii) a copy of the Sequence Listing in paper and computer readable form;

In response to the Notice Applicants provide herewith the following:

- (i) a statement that the content of the Substitute Sequence Listing information recorded in computer readable form is identical to the paper copy of the Substitute Sequence listing;
- (ii) a computer readable form of the Substitute Sequence Listing on a floppy disk;
- (iii) a copy of the Notice; and
- (iv) a preliminary amendment.

Applicants have provided herewith a Substitute Sequence Listing, submitted in computer readable form and paper copy in accordance with 37 C.F.R. §§ 1.821-1.825. SEQ ID NOS:8-24 describe these sequences as a “primer”, which are better described as “synthetic primer”. In the Substitute Sequence Listing the Numeric identifier field <223> has been amended from “primer” to --synthetic primer-- to comply to 37 CFR 1.823. New SEQ ID NO: 25 lists the sequence in figure 6. Thus no new matter is introduced by correcting the

original Sequence Listing. Applicants state that the Substitute Sequence Listing provided in paper copy and computer readable form is the same. Support for the sequences listed in the Substitute Sequence Listing may be found throughout the specification as filed. Therefore, in accordance with 37 C.F.R. § 1.821(g) the enclosed sequence listing does not constitute new matter.

The specification has been amended to add the SEQ ID NO and description from Figure 6 to paragraph [0033] and Table 13. Support for these amendments may be found in Figure 6 as originally filed. No new matter has been introduced by the foregoing amendments.

The Applicant does not believe that any additional fee is required in connection with the submission of this document. However, should any fee be required, or if any overpayment has been made, the Commissioner is hereby authorized to charge any fees, or credit any overpayments made, to Deposit Account 02-4377. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

BAKER BOTTS LLP



Lisa B. Kole
Patent Office Reg. No. 35,225
Attorney for Applicant

30 Rockefeller Plaza
New York, NY 10112-4498
(212)-408-2628